Rational drug design of orally active influenza neuraminidase inhibitors: Discovery and development of GS 4104

Medicinal Chemistry Research

Volumn 8, Issue 7-8, 1998, Pages 392-399

  Kim, Choung Un ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; GLYCEROL; OSELTAMIVIR; PRODRUG; SIALIC ACID; SIALIDASE INHIBITOR; VIRUS SIALIDASE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 0037976524     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Glezan, W. P. Serious morbidity and mortality associated with influenza epidemics. Epidemiol. Rev. 1982, 4, 25-44.
2. Hay, A. J. The action of adamantamines against influenza A viruses: Inhibition of the M2 ion channel protein. Semin. Virol. 1992, 3, 21-30.
3. Colman, P. M. In the influenza viruses: Influenza virus neuraminidase, enzyme and antigen. Krug, R. M., Ed.; Plenum Press: New York, 1989; pp 175-218.
4. Palese, P.; Tobita, K.; Ueda, M.; Compans, R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virol. 1974, 61, 397-410
5. Janakiraman, M. N.; White, C. L.; Laver, W. G.; Air, G. M. Structure of influenza virus neuraminidase B/Lee/40 complexed with sialic acid and a dehydro analog at 1.8Å resolution: Implication for the catalytic mechanism. Biochemistry 1994, 33, 8172-8179.
6. Varghese, J. N.; McKimm-Breschkin, J. L.; Caldwell, J. B.; Korzt, A.; Colman, P. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function and Genetics 1992, 14, 327-332.
7. Taylor, N. R.; Von Itzstein, M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J. Med. Chem. 1994, 37, 616-624.
8. Von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smyth, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woud, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature (London) 1993, 363, 418-423.
9. Fromtling, R. A.; Castaner, J. Zanamivir. Drugs Future, 1996, 21(4), 375-382.
10. Hayden, F. G.; Treanor, J. J.; Betts, R. F.; Lobo, M.; Esinhart, J. D.; Hussey, E. K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 1996, 275, 295-299.
11. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.; Bischofberger, N.; Chen, M. S.; Mendel, D. B.; Tai, C. Y.; Laver, W. G.; Stevens, R. C. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Amer, Chem. Soc. 1997, 119, 681-690.
12. Li, W.; Escarpe, P. A.; Eisenberg, E. J.; Cundy, K. C.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lew, W.; Williams, M. A.; Zhang, L.; Kim, C. U.; Bischofberger, N.; Chen, M. S.; Mendel, D. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob. Agents and Chemother. 1998, 42(3), 647-653.
13. Mendel, D. B.; Tai, C. Y.; Escarpe, P. A.; Li, W.; Sidwell, R. W.; Huffman, J. H.; Sweet, C.; Jakeman, K. J.; Merson, J.; Lacy, S. A.; Lew, W.; Williams, M. A.; Zhang, L.; Chen, M. S.; Bischofberger, N.; Kim, C. U. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob. Agents and Chemother. 1998, 42(3), 640-646.